Abstract

THE POTENCY OF HYDROXYCHLOROQUINE TO TREAT COVID- 19 DISEASE

E. M. Sutrisna*

Abstract

Background: several experts’ opinions, theory reviews and case reports on HCQ figure various results. This review is aimed at determining hydroxychloroquine (HCQ) effect on Covid-19 patient. Method: The Review was done by examining publications published in Pubmed and Sciencedirect. Searching process was done by keywords: hydroxychloroquine and covid-19 and randomized clinical trial; research article and published 2020. The criterion for the choice of publications to be reviewed is the complete researches based articles. Result: There were 3 articles meet the criterion. Length of stay (hospitalization) to negative convertion of viral nucleic acid in HCQ vs control group was 4 (1.9) days vs 2 (1.4) days, (Z = 1.27, P>0.05); number of patients who get diarrhea and abnormal liver function between HCQ vs control groups were 4 cases (26.7%)) vs 3 cases (20%) (P>0.05); number of patients who get radiological progression that shown on CT images between HCQ vs control groups were 5 cases (33.3%) vs 7 cases (46.7%); The median time to normalize body temperature in the HCQ vs control group was 1 (0.2) vs 1 (0.3) day). Total negative conversion before 28 days between HCQ (1200mg/day for 3 days followed 800mg/day for2-3 weeks) +standard care group vs standard care group was (56 vs 53 patients of 150 patients). There were 2 HCQ recipients (1200mg/day for 3 days followed 800mg/day for2-3 weeks) were reported to have serious adverse events blurred vision and thirst. Conclusion: There is insufficient evidence that HCQ improve clinical symptom, sign or time hospitalization on covid-19 patients.

Keywords: hydroxychloroquine (HCQ), Covid-19, Review article.